Table F.1.

Antimicrobials reported, methods used, type of data reported and interpretive criteria applied by MSs for human Salmonella AST data in 2021

Country	Gentamicin	Chloramphenicol	Ampicillin	Cefotaxime	Ceftazidime	Meropenem	Tigecycline	Nalidixic acid	Ciprofloxacin/pefloxacin	Azithromycin	Colistin	Sulfonamides	Trimethoprim	Trimethoprim‐sulfa	Tetracyclines	Method used	Quantitative (Q) or categorical (SIR or PWT/PNWT)	Interpretive criteria
Austria	●	●	●	●	●	●	●	●	● (a)	●		●	●		●	DD	Q	Interpreted by ECDC. EUCAST ECOFFs for all except CLSI CBP for SUL
Belgium	●	●	●	●		●			●			●	●		●	DL	Q	Interpreted by ECDC, as for Austria.
Bulgaria	●		●		●	●					●		●			DL	Q	Interpreted by ECDC, as for Austria except for MEM where EUCAST CBP were used.
Cyprus	●		●	●	●	●			●		●			●		DL/DLG	Q	Interpreted by ECDC, as for Austria, except for CTX, MEM and SXT where EUCAST CBP were used.
Denmark	●	●	●	●	●	●	●	●	●	●	●	●	●		●	DL	Q	Interpreted by ECDC, as for Austria. MIC ECOFF for TGC according to EFSA reporting manual 2021.
Estonia	●	●	●	●	●	●	●	●	●		●	●	●		●	DL	Q	Interpreted by ECDC, as for Austria.
Finland	●	●	●	●		●		●	● (a)				●		●	DD	Q	Interpreted by ECDC, as for Austria.
France	●	●	●	●	●	●	●	●	●	●	●	●	●		●	DL	Q	Interpreted by ECDC, as for Austria. MIC ECOFF for TGC according to EFSA reporting manual 2021.
Germany	●	●	●	●	●	●		●	●				●	●	●	DL	Q	Interpreted by ECDC, as for Austria.
Greece	●	●	●	●	●	●		●	● (a)	●		●	●		●	DD	Q	Interpreted by ECDC, as for Austria.
Hungary	●	●	●	●	●	●			●				●	●	●	DD	SIR	EUCAST CBP except CLSI CBP for NAL, SUL and TET
Iceland			●						● (a)					●		DD	Q	Interpreted by ECDC, as for Austria.
Italy	●	●	●	●	●	●	●	●	● (a)	●	●	●	●		●	DD/DL	Q	Interpreted by ECDC, as for Austria.
Latvia			●						●				●	●		DD	SIR	No recent information on guidelines used.
Lithuania	●	●	●	●	●	●			●				●	●		DL/DD	SIR	EUCAST CBP
Luxembourg	●	●	●	●	●	●			● (a)			●		●	●	DD/DLG	Q	Interpreted by ECDC, as for Austria.
Malta	●		●	●	●	●			● (a)							DL/DLG/DD	Q	Interpreted by ECDC, as for Austria, except for CTX and MEM where EUCAST CBP were used.
Netherlands	●	●	●	●	●	●	●	●	●	●	●	●	●		●	DL	Q	Interpreted by ECDC, as for Austria. MIC ECOFF for TGC according to EFSA reporting manual 2021.
Norway		●	●	●	●	●			● (a)						●	DD	Q	Interpreted by ECDC, as for Austria.
Poland	●	●	●	●	●	●	●	●	●	●	●		●	●	●	DD/DLG/DL	Q	Interpreted by ECDC, as for Austria. MIC ECOFF for TGC according to EFSA reporting manual 2021.
Portugal	●	●	●	●	●	●	●	●	● (a)	●		●	●		●	DD	Q	Interpreted by ECDC, as for Austria.
Romania	●	●	●	●	●	●		●	● (a)			●	●	●	●	DD	Q	Interpreted by ECDC, as for Austria.
Slovakia		●	●	●	●	●			●					●	●	DD/DL	SIR	EUCAST CBP except CLSI CBP for NAL, SUL and TET.
Slovenia	●	●	●	●	●	●			● (a)			●	●	●	●	DD/DLG	Q	Interpreted by ECDC, as for Austria.
Spain	●	●	●	●	●	●		●	● (a)			●	●		●	DD	Q	Interpreted by ECDC, as for Austria.
Sweden	●	●	●	●	●	●	●		●	●	●	●	●		●	WGS	PWT/PNWT	Sequencing results interpreted by the laboratory with NCBI AMRFinder and CGE ResFinder and PointFinder

AST: antimicrobial susceptibility testing; CBP: clinical breakpoint; DD: disk diffusion; DL: dilution; DLG: dilution with gradient strip; WGS: whole genome sequencing; Q: quantitative data; SIR: susceptible standard dosing regimen, susceptible increased exposure, resistant (categorical data); PWT/PNWT: predicted wild type/predicted non‐wild type (categorical); ECDC: European Centre for Disease Prevention and Control; ECOFF: epidemiological cut‐off; CLSI: Clinical and Laboratory Standards Institute; EUCAST: European Committee on Antimicrobial Susceptibility Testing; NCBI: National Center for Biotechnology Information, US; CGE: Center for Genomic Epidemiology, Denmark; MIC: minimum inhibitory concentration; AZM: azithromycin; CTX: cefotaxime; GEN: gentamicin; MEM: meropenem; NAL: nalidixic acid; SUL: sulfonamides; TET: tetracycline.

^(a)Pefloxacin used in disk diffusion.